Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial

Table 6 Logistic regression model for factors predictive of hepatic steatosis in patients with hepatitis C virus after 12 wk of protein supplementation

	Bivariate analysis		Multivariate analysis
	Crude OR (95% IC)	P value	Adjusted OR1 (95% IC)	P value
Groups
Control-casein	1		1
IG-soy	0.51 (0.20-1.22)	0.135	0.25 (0.06-0.82)	0.032
HOMA-IR
< 3.0	1		1
≥ 3.0	1.97 (0.82-4.77)	0.129	3.49 (1.10-11.90)	0.037
Stage of fibrosis
F0/F1/F2	1		1
F3/F4	1.78 (0.68-4.69)	0.239	1.59 (0.50-5.40)	0.436
γGT
< 85 U/L	1		1
≥ 85 U/L	2.07 (0.81-5.64)	0.135	1.52 (0.47-5.18)	0.487
HDL-C
≥ 35 mg/dL	1		1
< 35 mg/dL	1.25 (0.41-3.40)	0.677	2.18 (0.56-8.21)	0.247

¹Adjusted for the other variables shown in the table; γGT: 85 U/L upper limit of normal. γGT: Gamma glutamyl transferase; HOMA-IR: Homeostasis model assessment index of insulin resistance; HDL: High density lipoprotein; IG-soy: Intervention-soy; OR: Odd ratio; 95% IC: 95% confidence interval.